← All trials
NCT05184452
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2021
- Primary completion
- Nov 30, 2022
- Completion date
- Nov 30, 2022
- First posted
- Jan 11, 2022
- Last posted
- Sep 16, 2022
- Enrollment
- 95
- Arms / groups
- 10 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- National Institutes of Health (NIH)Collaborator
- Centre for the AIDS Programme of Research in South AfricaStudy chair
- Emory UniversityStudy chair
- George Washington UniversityStudy chair
- Department of Health and Human ServicesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.